Abstract
Immune check point inhibitors are now commonly used in cancer treatment regimens. Pembrolizumab acts by binding and blocking of the Program cell Death 1 Ligand (PDL1) receptor on T cells and augments T cell antitumor activity. Pembrolizumab has been associated with various immune related adverse effects like thyroiditis, hypophysitis, adrenal insufficiency and less commonly Diabetes mellitus (DM). We present a case of a patient treated with Pembrolizumab (PDL1 Antagonist) for renal cell carcinoma who was diagnosed with new onset DM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
